Your browser doesn't support javascript.
loading
Switching from originator infliximab to biosimilar CT-P13 compared with maintained treatment with originator infliximab (NOR-SWITCH): a 52-week, randomised, double-blind, non-inferiority trial.
Jørgensen, Kristin K; Olsen, Inge C; Goll, Guro L; Lorentzen, Merete; Bolstad, Nils; Haavardsholm, Espen A; Lundin, Knut E A; Mørk, Cato; Jahnsen, Jørgen; Kvien, Tore K.
Afiliación
  • Jørgensen KK; Department of Gastroenterology, Akershus University Hospital, Lørenskog, Norway.
  • Olsen IC; Department of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway.
  • Goll GL; Department of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway.
  • Lorentzen M; Department of Dermatology, Oslo University Hospital, Rikshospitalet, Oslo, Norway.
  • Bolstad N; Department of Medical Biochemistry, Oslo University Hospital, Radiumhospitalet, Oslo, Norway.
  • Haavardsholm EA; Department of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway; Faculty of Medicine, University of Oslo, Oslo, Norway.
  • Lundin KEA; Department of Gastroenterology, Oslo University Hospital, Rikshospitalet, Oslo, Norway; Faculty of Medicine, University of Oslo, Oslo, Norway; Centre for Immune Regulation, University of Oslo, Oslo, Norway.
  • Mørk C; Institute of Cancer Research and Molecular Medicine, Faculty of Medicine, Norwegian University of Science and Technology, Trondheim, Norway.
  • Jahnsen J; Department of Gastroenterology, Akershus University Hospital, Lørenskog, Norway; Faculty of Medicine, University of Oslo, Oslo, Norway.
  • Kvien TK; Department of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway; Faculty of Medicine, University of Oslo, Oslo, Norway. Electronic address: t.k.kvien@medisin.uio.no.
Lancet ; 389(10086): 2304-2316, 2017 06 10.
Article en En | MEDLINE | ID: mdl-28502609
Asunto(s)
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Fármacos Gastrointestinales / Biosimilares Farmacéuticos / Infliximab / Anticuerpos Monoclonales Tipo de estudio: Clinical_trials / Guideline Límite: Female / Humans / Male / Middle aged País/Región como asunto: Europa Idioma: En Revista: Lancet Año: 2017 Tipo del documento: Article País de afiliación: Noruega
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Fármacos Gastrointestinales / Biosimilares Farmacéuticos / Infliximab / Anticuerpos Monoclonales Tipo de estudio: Clinical_trials / Guideline Límite: Female / Humans / Male / Middle aged País/Región como asunto: Europa Idioma: En Revista: Lancet Año: 2017 Tipo del documento: Article País de afiliación: Noruega